Myelodysplastic syndromes
=========================

Myelodysplastic syndromes (MDS) are a group of bone marrow disorders characterized by ineffective hematopoiesis resulting in anemia, neutropenia, and thrombocytopenia ([@b4]; [@b41]; [@b3]). MDS can be classified as de novo, arising from no apparent cause, or as secondary, resulting from exposure to a mutagen such as chemotherapy or benzene ([@b4]; [@b5]). Chromosomal abnormalities are common in both types of MDS ([@b32]; [@b34]; [@b4]; [@b3]). In patients with de novo MDS, chromosomal abnormalities have been reported in approximately 40%--70% of cases, whereas in patients with secondary MDS, chromosomal abnormalities are observed in almost 95% of cases ([@b34]). MDS occurs primarily in the elderly and is rare in young adults ([@b68]; [@b6]; [@b4]; [@b3]).

Although the exact number of MDS cases is unknown owing to the lack of a central United States registry, it is estimated that, in the general population, MDS occurs in 5 per 100,000 people ([@b43]). Estimates range between 10,000 and 20,000 new cases of MDS per year in the United States ([@b4]; [@b5]). The number of MDS cases is believed to be increasing as a result of the aging population and the increased survival rate of patients who have received chemotherapy ([@b4]).

The greatest risk factor for MDS appears to be advancing age, with 80%--90% of all patients over 60 years old ([@b4]). Other risk factors for MDS are previous chemotherapy, exposure to environmental toxins, tobacco and cigarette smoke, congenital disorders, familial disorders, and being of male gender ([@b4]). Clinical symptoms may include fatigue, weakness, and serious infections; however, approximately half of MDS patients are asymptomatic at the time of initial diagnosis and are diagnosed only after routine laboratory tests show abnormalities ([@b23]; [@b4]; [@b5]). Although MDS can eventually result in neutropenia and/or thrombocytopenia, anemia is the most common characteristic at the time of initial diagnosis. In the early course of the disease, a hemoglobin value of less than 10 g/dL has been observed in approximately 80% of patients ([@b23]).

Prognosis can depend on many variables, including morphology, number of cytopenias, blast count, and cytogenetics. Left untreated, the median survival ranges from 0.4 years for high-risk MDS patients to 5.7 years for low-risk MDS patients ([@b22]). In the majority of MDS patients, death typically results from complications of bone marrow failure, such as chronic anemia, infections, or severe bleeding ([@b32]; [@b42]). Approximately one-third of adult MDS patients progress to acute myeloid leukemia (AML), with a median survival of 6--12 months ([@b18]; [@b22]).

Classification systems
======================

At the present time there are two MDS classification systems that have been used to determine expected median survival and median time to AML transformation. The French-American-British (FAB) Co-operative Group Classification recognizes five subgroups of MDS based on cell morphology and the percentage of blasts ([@b7]). In order to improve the prognostic value, the World Health Organization (WHO) subsequently made modifications to FAB that included the reduction of the blast threshold for the diagnosis of AML and refinements of the categories of refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS) ([@b65]).

There has also been the development of a widely used prognostication tool, the International Prognostic Scoring System (IPSS), which takes into account cytogenetics and number of cytopenias as well as morphology ([@b22]; [@b32]). The IPSS scoring system subdivides MDS into four distinct subgroups for predicting survival and risk of transformation to AML ([Table 1](#tbl1){ref-type="table"}) ([@b22]).

###### 

International prognostic scoring system (IPSS) score and prognosis

                                               Score[a](#tf1-1){ref-type="table-fn"}                                                                                                       
  -------------------------------------------- --------------------------------------- -------------------------------------------------------------- --------------------------- -------- --------
  Marrow blasts (%)                            \<5                                     5--10                                                          ---                         11--20   21--30
  Karyotype[b](#tf1-2){ref-type="table-fn"}    Good                                    Intermediate                                                   Poor                        NA       NA
  Cytopenias[c](#tf1-3){ref-type="table-fn"}   0/1                                     2/3                                                            NA                          NA       NA
                                                                                                                                                                                           
  **Combined prognosis score**                 **IPSS subgroup**                       **Median time to AML transformation, 25% of patients (yrs)**   **Medial survival (yrs)**            
                                                                                                                                                                                           
  0                                            Low                                     9.4                                                            5.7                                  
  0.5--1.0                                     Intermediate-1                          3.3                                                            3.5                                  
  1.5--2.0                                     Intermediate-2                          1.1                                                            1.2                                  
  \>2.5                                        High                                    0.2                                                            0.4                                  

Based on the combined score, four risk groups have been identified: low (combined score: 0), intermediate-1 (combined score: 0.5--1), intermediate-2 (combined score: 1.5--2), and high (combined score: \>2).

Good: diploid, -Y (loss of the Y chromosome); del(5q), del(20q), deletion of 5q and 20q chromosomes; poor: complex, chromosome 7 abnormalities; intermediate: others.

Hemoglobin \<10g/dL, neutrophils \<1.5 × 10^9^/L, platelets \<100 × 10^9^/L.

NA, not applicable; AML, acute myeloid leukemia.

**Source:** Adapted, with permission, from "International scoring system for evaluating prognosis in myelodysplastic syndromes" ([@b22]) p2085. Copyright 1997 by the American Society of Hematology.

Clinical practice guidelines
============================

Evidence-based treatment guidelines for MDS have recently been published by the Italian Society of Hematology, the United Kingdom, and the United States (National Comprehensive Cancer Network \[NCCN\]) ([@b2]; [@b8]; [@b43]). According to these guidelines, the treatment strategy for MDS should be determined by IPSS risk category, as well as age and performance status. The recently updated NCCN guidelines recommend hypomethylating agents, such as decitabine or azacitidine, for the treatment of higher risk MDS patients and for lower risk MDS patients who are nonresponsive to growth factor therapy or who are HLA-DR15 negative ([@b43]).

Treatment options
=================

The MDS patient population presents many challenges when considering an appropriate treatment strategy, including advanced age, comorbidities, and an inability to tolerate certain types of intensive therapy. Therapy should be selected based on the patient's performance status, disease classification, IPSS score, and treatment tolerance. In patients with a low-risk or intermediate-1 IPSS score, the goals of therapy are to improve blood counts and ensure age-related quality of life ([@b43]), whereas for intermediate-2 and high-risk patients, the goals of therapy are to prolong survival and delay leukemic progression ([@b43]). The only potentially curative treatment for MDS is hematopoietic stem cell transplantation (HSCT), however, this option is available for only a small number of patients (ie, younger age, histocompatible donor, no significant comorbidities) ([@b2]; [@b8]; [@b43]). Some high-risk MDS patients who are not candidates for HSCT may be eligible for intensive antileukemic chemotherapy ([@b2]; [@b8]; [@b43]). Nevertheless, the vast majority of MDS patients are managed with supportive care, including red blood cell (RBC)/platelet transfusions, growth factors such as recombinant erythropoietin and colony-stimulating factors, and antibiotics, including broad coverage in neutropenic patients as infection occurs.

A number of emerging therapeutic options are currently being evaluated for the treatment of MDS that will, it is hoped, add to the treatment options for patients who are ineligible to receive HSCT or intensive chemotherapy. Lenalidomide, an immunomodulatory drug derived from thalidomide, has been recently approved by the Food and Drug Administration (FDA) and is indicated for the treatment of MDS in patients with chromosome 5q deletion. Other agents such as imatinib and tipifarnib are currently being evaluated in clinical trials ([@b12]; [@b17]; [@b59]; [@b26]). Some of the therapies farthest along in development are the hypomethylating agents decitabine and azacitidine, both of which have been recently approved by the FDA for the treatment of MDS.

Hypermethylation in cancer
==========================

DNA methylation is a common epigenetic modification that plays an important role in gene expression in mammalian cells ([@b33]; [@b15]). As part of normal development, certain genes may be silenced through methylation of cytosine residues in their promotor regions (CpG islands). However, in some hematopoietic neoplasms including MDS, DNA hypermethylation can inactivate genes essential for the control of normal cell growth, differentiation, or apoptosis. A group of enzymes called DNA methyltransferases (DNMTs) catalyze the methylation of cytosine residues in newly synthesized DNA, thus replicating the methylation signal. In recent years, there has been interest in pharmacologic therapies that target this mechanism by inhibiting DNMT, resulting in hypomethylation of the DNA and re-expression of tumor suppressor genes. Cytosine analogues such as decitabine have been shown to inhibit DNMT and are being used against MDS, as well as AML and other cancers ([@b33]; [@b15]).

Multiple genes appear to be hypermethylated in MDS, including p15^*INK4B*^, which encodes a cell-cycle inhibitor. Evidence suggests that p15^*INK4B*^ methylation is correlated with blastic bone marrow involvement and that it increases during disease progression to AML ([@b49]; [@b48]). Methylation of the p15^INK4B^ gene may allow leukemic cells to escape the inhibitory signals in the bone marrow ([@b49]; [@b48]). Decitabine treatment has been shown to reverse hypermethylation of p15^*INK4B*^, allowing for re-establishment of normal p15^*INK4B*^ protein expression ([@b16]). In addition, hypomethylation of p15^INK4B^ has been associated with hematologic response, supporting pharmacologic demethylation as a possible mechanism for clinical response ([@b16]).

Decitabine is believed to have a dual mechanism of action depending on dose. At both lower and higher doses, decitabine incorporates into DNA; however, at higher doses, decitabine inhibits cell proliferation through nonreversible covalent linking with DNA methyltransferase and blocking of DNA synthesis ([@b33]). At lower doses, decitabine induces hypomethylation, thereby promoting cell differentiation, re-expression of tumor suppressor genes, stimulation of immune mechanisms, and suppression of tumor growth ([@b33]; [@b40]).

Description and structure of decitabine
=======================================

Decitabine (5-aza-2'-deoxycytidine) is a cytosine analogue modified in position 5 of the pyrimidine ring ([Figure 1](#fig1){ref-type="fig"}). Decitabine is slightly soluble in ethanol/water (50/50), methanol/water (50/50), and methanol; sparingly soluble in water; and soluble in dimethylsulfoxide (DMSO). Decitabine (Dacogen™ for Injection) is a white to almost-white sterile lyophilized powder supplied in a clear, colorless glass vial ([@b14]).

![Decitabine structure.](tcrm0305-807-01){#fig1}

Pharmacokinetics
================

Decitabine distributes extensively throughout human tissues. In a phase 1 pharmacokinetic study of decitabine in 21 patients with advanced solid tumors, the mean value of volume of distribution was found to be 4.59 L/kg ± 1.42 ([@b64]). Although the exact route of elimination and metabolic fate of decitabine is unknown in humans, high total body clearance values and a total urinary excretion of less than 1% of the administered dose suggest that decitabine is eliminated rapidly and primarily through enzymatic metabolism ([@b64]).

In a more recent pharmacokinetic phase 1 study, 16 patients with MDS/AML were administered decitabine at a dose of 15 mg/m^2^ as a 3-hour infusion every 8 hours for 3 consecutive days of a 6-week cycle for two cycles ([@b9]). Preliminary results suggest that repeated administration of decitabine does not result in systemic accumulation of the drug. For the five patients who received decitabine for two cycles, maximum concentration (C~max~) values for Cycle 1 (49.0 ± 22.2 ng/mL) and Cycle 2 (62.7 ± 45.2 ng/mL) were comparable, suggesting that decitabine pharmacokinetics remain unchanged from cycle to cycle.

Clinical studies of decitabine
==============================

Phase 2 studies of decitabine in MDS patients yielded encouraging response rates, including overall responses (complete response \[CR\] + partial response \[PR\]) of 26%--45% and complete responses of 21%--28% ([@b67]; [@b66]; [@b53]; [@b54]). These results led to a North American, multicenter phase 3 study of decitabine compared with supportive care in 170 MDS patients, which formed the basis for the FDA approval of decitabine ([@b52]; [@b28]). Patients were stratified by IPSS risk group and type of MDS (de novo or secondary) and randomly assigned to receive either supportive care alone or decitabine at a dose of 15 mg/m^2^ as a 3-hour infusion every 8 hours for 3 days, repeated every 6 weeks, plus supportive care. Primary endpoints were overall response rate (ORR) and time to AML transformation or death. Responses were assessed using the International Working Group (IWG) criteria ([@b10]), which defined a CR as normalization of peripheral counts and bone marrow for at least 8 weeks with serial bone marrow blasts less than 5% without dysplastic changes, hemoglobin greater than 11 g/dL, a neutrophil count 1.5 × 10^9^/L or greater, and a platelet count of 100 × 10^9^/L or greater. A PR was defined similarly to CR except for the reduction of ≥50% of blasts that remained above 5%, or a downgrade in the FAB criteria. Response criteria had to be met for at least 8 weeks. The study design dictated that patients be removed from therapy after two cycles of a maintained CR.

The results of the phase 3 study indicate that decitabine is clinically effective in patients with MDS. Patient baseline characteristics were well balanced between the two study arms. Responses were defined according to strict IWG criteria ([@b10]). The ORR of patients in the decitabine arm was 17% compared with 0% in the supportive care only arm (p \< 0.001) ([Table 2](#tbl2){ref-type="table"}). In decitabine-treated patients considered evaluable for response (ie, those patients with pathologically confirmed MDS at baseline who received at least two cycles of treatment), the ORR was 21% (12/56) ([@b37]). Responses were observed across all IPSS risk groups and were found to be durable, with a median duration of response of 10.3 months ([Table 2](#tbl2){ref-type="table"}). Median time to first response (PR or CR) was 3.3 months ([Table 2](#tbl2){ref-type="table"}). Hematologic improvement (HI) was observed in an additional 13% of patients in the decitabine group versus 7% in the supportive care arm. The overall improvement rate for patients receiving decitabine was 30% versus 7% for patients receiving supportive care. Patients in the decitabine arm had a median time to AML or death that was 4.3 months greater than that of patients in the supportive care only arm (p = 0.16) ([Figure 2A](#fig2){ref-type="fig"}). When patient subgroups were analyzed, patients receiving decitabine experienced a longer time to AML or death than patients receiving supportive care only (treatment-naïve \[12.3 vs 7.3 months; p = 0.08\] \[[Figure 2B](#fig2){ref-type="fig"}\], IPSS risk of intermediate-2/high-risk patients \[12.0 vs 6.8 months; p = 0.03\] \[[Figure 2C](#fig2){ref-type="fig"}\], IPSS high-risk patients \[9.3 vs 2.8 months; p = 0.01\], or de novo MDS \[12.6 vs 9.4 months; p = 0.04\]).

![Time to acute myeloid leukemia (AML) or death: (**A**) all patients; (**B**) treatment-naïve patients; (**C**) International Prognostic Scoring System subgroups intermediate-2 to high-risk patients. (Reprinted, with permission, from [@b28]).](tcrm0305-807-02){#fig2}

###### 

Response to decitabine (ITT) using the FDA approved dose of 15 mg/m^2^ over 3 hours every 8 hours ×3 days every 6 weeks (Adapted, with permission, from [@b28])

  International working group response rate, onset, and duration   Decitabine (n = 89)   Supportive care (n = 81)
  ---------------------------------------------------------------- --------------------- --------------------------
  Overall response rate (CR + PR)                                  15(17%)\*             0(0%)
  CR                                                               8(9%)                 0(0%)
  PR                                                               7(8%)                 0(0%)
  HI                                                               12(13%)               6(7%)
  \*p-value \< 0.001 from two-sided Fisher's exact test                                  
                                                                                         
  Onset and duration of response (months)                                                
  Median time to (CR + PR) response                                3.3(2.0 -- 9.7)       
  Median duration of (CR + PR) response                            10.3(4.1 -- 13.9)     N/A

**Abbreviations:** ITT, intention to treat; CR, complete response; PR, partial response; HI, hematologic improvement.

All responders in the phase 3 study, defined as patients achieving a CR or PR, became RBC and platelet transfusion independent in the absence of growth factors during the time of the response ([@b52]; [@b54]; [@b28]). The percentage of patients in the decitabine arm who became RBC transfusion independent increased with increased number of treatment cycles, while the percentage of patients on supportive care who required RBC transfusions did not change ([Figure 3](#fig3){ref-type="fig"}). All eight responders who had cytogenetic abnormalities at baseline and were evaluable for cytogenetic response achieved a cytogenetic response (seven major responses and one minor response). The median number of cycles delivered was three, with 43 of 89 patients receiving two or more cycles. Of the 15 patients who responded after decitabine treatment, the median number of courses was six. In contrast, the median number of cycles in the phase 2 studies was four, which may in part explain the slightly higher response rates in the phase 2 studies ([@b53]). The authors of the phase 3 study speculate that greater benefit may have been observed if the study design had allowed patients to continue receiving decitabine therapy for a longer period of time.

![Percentage of patients red blood cell (RBC) transfusion free per cycle (Reprinted, with permission, from [@b28]).](tcrm0305-807-03){#fig3}

Safety data were evaluated for 83 patients treated with decitabine and 81 patients who received supportive care only. Overall, decitabine therapy was well tolerated with manageable adverse effects. The most common adverse effects included myelosuppression (neutropenia, thrombocytopenia, and anemia), pyrexia, fatigue, nausea, cough, petechiae, diarrhea, and constipation ([Table 3](#tbl3){ref-type="table"}). Febrile neutropenia occurred in 28% of patients who received decitabine. The authors noted that neutropenia, thrombocytopenia, anemia, and leukopenia appeared to diminish in incidence over the first four cycles of decitabine treatment; however, these toxicities remained frequent, most likely owing to the continuing presence of underlying disease and myelosuppression.

###### 

Most common adverse events of decitabine

  --------------------------------------------------------------------------------------
                        Decitabine %\                               Supportive care %\
                        (n = 83)[\*](#tf3-1){ref-type="table-fn"}   (n = 81)
  --------------------- ------------------------------------------- --------------------
  Neutropenia           90                                          72

  Thrombocytopenia      89                                          79

  Anemia NOS            82                                          74

  Pyrexia               53                                          28

  Nausea                42                                          16

  Cough                 40                                          31

  Petechiae             39                                          16

  Constipation          35                                          14

  Diarrhea NOS          34                                          16

  Hyperglycemia NOS     33                                          20

  Febrile neutropenia   29                                          6

  Leukopenia NOS        28                                          14

  Headache              28                                          14

  Insomnia              28                                          14

  Edema, peripheral     25                                          16

  Vomiting NOS          25                                          9

  Hypoalbuminemia       24                                          17

  Hypomagnesemia        24                                          7

  Pallor                23                                          12

  Pneumonia NOS         22                                          14

  Rigors                22                                          17

  Ecchymosis            22                                          15

  Hypokalemia           22                                          12

  Arthralgia            20                                          10
  --------------------------------------------------------------------------------------

Adverse events reported in ≥20% of patients in the decitabine group and at a rate greater than supportive care in the phase 3 myelodysplastic syndromes trial. NOS, not otherwise specified.

Decitabine has also been studied in MDS patients with disease recurrence who had previously responded to the drug. Rüter and colleagues reported recently on 22 patients who received decitabine retreatment at the time of disease relapse ([@b36]; [@b51]). These patients had initially received a median of six courses of decitabine (range 2--6 courses), which resulted in a CR in 55% (12 of 22 patients), a PR in 27% (6 of 22), and a hematologic improvement in 18% (4 of 22). Decitabine retreatment was initiated at a median of 11 months after the last course of initial treatment. In the retreatment stage, patients received a median of three courses, resulting in 45% (10 of 22 patients) of patients responding (7 HI, 2 PR, and 1 CR). The median duration of second response was 4 months. Because the quality and duration of the second response were inferior to those of the first response, the authors suggest that decitabine responders may derive more clinical benefit from a longer period of initial treatment.

Optimal dosing of decitabine
============================

As previously described, decitabine is believed to have a dual mechanism of action depending on dose, with higher doses associated with cytotoxicity and lower doses associated with demethylation. Because of this dose-dependent mechanism of action, lower-dose schedules of decitabine may be safer and more effective than higher dose schedules. Indeed, early studies of decitabine using high doses of the drug showed activity in various types of hematologic malignancies but with significant prolonged myelosuppression ([@b57]). In a more recent study, decitabine appeared significantly more active at lower doses compared with higher doses ([@b24]).

In order to further optimize therapy with decitabine, Kantarjian and colleagues performed a randomized study of three low-dose schedules in patients with MDS and chronic myelomonocytic leukemia (CMML) ([@b44]; [@b29]; [@b30]). The decitabine dose per course was reduced from the FDA approved dose of 135 mg/m^2^ to 100 mg/m^2^. In addition, the doses of decitabine were delivered every 4 weeks (rather than every 6--8 weeks), as long as there was persistent disease and no significant myelosuppression-associated complications, and therapy was continued for at least three courses before response was evaluated. The three dosing schedules were as follows: 20 mg/m^2^ intravenously (IV) over 1 hour daily for 5 days (arm A), 10 mg/m^2^ IV over 1 hour daily for 10 days (arm B), and 10 mg/m^2^ subcutaneously (SQ) given twice daily for 5 days (arm C).

The results of the study by Kantarjian and colleagues indicate that lower dose schedules of decitabine have higher efficacy in MDS patients ([@b44]; [@b29]; [@b30]). At least one course of therapy was received by 95 patients. Response criteria for CR and PR were the same as for AML (PR also requiring a decrease in blasts by \>50%) but required response durability for at least 4 weeks. In total, 32 patients had a CR (34%), 1 patient had a PR (1%), 23 patients (24%) had marrow CR without (n = 10, 11%) or with other HI responses (n = 13, 14%), and 13 patients had an HI (14%). When analyzed by schedule, the complete response rates were 39% for arm A, 24% for arm B, and 21% for arm C ([Table 4](#tbl4){ref-type="table"}). The median number of courses to reach CR for all treatment groups was three (range, 1--7). Myelosuppression was the primary toxicity reported and it occurred more with arm B ([Table 4](#tbl4){ref-type="table"}). In summary, the schedule of 20 mg/m^2^ IV over 1 hour daily for 5 days was found to be superior to the other two regimens and to offer an excellent therapeutic option in addition to the FDA approved dose ([Table 5](#tbl5){ref-type="table"}).

###### 

Efficacy and side effects of three alternative decitabine dosing schedules (Adapted, with permission, from [@b30])

  Parameter                                                   Arm A (5-Day IV)   Arm B (10-Day IV)   Arm C (5-Day SQ)
  ----------------------------------------------------------- ------------------ ------------------- ------------------
  No. patients                                                64                 17                  14
  No. CR/treated (%)                                          25(39)             4(24)               3(21)
  Median number of courses (range)                            5(1--18)           9(1--15)            8(1--17)
  Median duration of therapy in mos (range)                   5.4(1.0--20.4+)    10.8(1.9--17.7+)    9.7(0.5--22.9+)
  Median follow-up time (mos)                                 6.5                15                  15
  No. (%) still on therapy                                    39(61)             6(35)               3(21)
  Median days to granulocytes recovery to 10^9^/L or above    24                 27                  14
  Median days to platelet recovery to 50 × 10^9^/L or above   20                 27                  31
  Median days to delivery of subsequent courses (range)       35                 40                  35
  No. courses requiring hospitalization (%)                   50(12)             23(23)              14(14)

**Abbreviations:** IV, intravenous; SQ, subcutaneous; CR, complete response.

###### 

Decitabine dosing schedules

  Dacogen regimen                                      IV Dose and schedule                                           Total dose/course
  ---------------------------------------------------- -------------------------------------------------------------- -------------------
  FDA approved[\*](#tf5-1){ref-type="table-fn"}        15 mg/m^2^ over 3 hours every 8 hours × 3 days every 6 weeks   135 mg/m^2^
  Active alternative[†](#tf5-2){ref-type="table-fn"}   20 mg/m^2^ over 1 hour daily × 5 days every 4 weeks            100 mg/m^2^

[@b28]

[@b30]

Approved indications for decitabine
===================================

Decitabine is approved for the treatment of patients with MDS, including previously treated or untreated, de novo or secondary MDS of all FAB subtypes (RA, RARS, RAEB, RAEB-T, and CMMoL) and intermediate-1, intermediate-2, and high-risk IPSS groups ([@b14]). Decitabine dosing for MDS is 15 mg/m^2^ via a 3-hour continuous infusion three times a day for 3 days for the first treatment cycle, repeated every 6 weeks. It is recommended that patients be treated for a minimum of four cycles; however, it is noted that a complete or partial response may take longer than four cycles. Treatment may be continued as long as the patient continues to benefit. Patients may be premedicated with standard antiemetic therapy.

Decitabine treatment is associated with myelosuppression, so complete blood counts are recommended before each cycle of therapy, or as needed to assess toxicity ([@b14]). After the first cycle of therapy, dose adjustments and delays may be required and are outlined in the package labeling. Clinicians should consider the early administration of growth factors and/or antimicrobial agents for prevention or treatment of infections. Myelosuppression and worsening neutropenia may occur more frequently in the first or second treatment cycles, and may not necessarily indicate progression of underlying MDS. Decitabine is contraindicated in patients with a known hypersensitivity to decitabine and carries a pregnancy category D rating.

Preparation and stability
=========================

Decitabine should be aseptically reconstituted with 10 mL of Sterile Water for Injection (USP) ([@b14]). Immediately after reconstitution, the solution should be further diluted with 0.9% sodium chloride injection, 5% dextrose injection, or lactated Ringer's injection to a final drug concentration of 0.1--1.0 mg/mL. Unless used within 15 minutes of reconstitution, the diluted solution must be prepared using cold (2 °C--8 °C) infusion fluids and stored at 2 °C--8 °C (36 °F--46 °F) for up to a maximum of 7 hours until administration.

Azacitidine
===========

Azacitidine is the only other approved hypomethylating agent for the treatment of MDS. Although similar in structure to decitabine, azacitidine contains ribose rather than deoxribose and is incorporated primarily into RNA and to a much lesser extent into DNA. This difference may account for the approximately 10-fold higher potency of decitabine compared with azacitidine ([@b13]).

In a randomized phase 3 trial of azacitidine in patients with MDS, azacitidine produced results similar to decitabine, with an ORR (CR + PR) in the azacitidine arm of 16.2% compared to 0% in the supportive care arm (p \< 0.0001) ([@b61]; [@b27]). The CR rate in patients treated with azacitidine was 6.1% compared with 0% for patients treated with supportive care. Median time to AML or death was significantly increased with azacitidine treatment (21 months compared with 13 months for supportive care). As expected for this class of agent, the most common treatment-related toxicity was myelosuppression.

Because of the lack of any head-to-head trials, it is difficult to compare the efficacy of decitabine and azacitidine. Differences in study design between the two completed phase 3 trials add to this difficulty. Patients in the phase 3 azacitidine study were able to stay on treatment longer, resulting in a median of nine treatment cycles ([@b61]), compared with those in the phase 3 decitabine trial who received a median of three treatment cycles ([@b28]). The median duration of MDS was 7.3 months in the decitabine study compared with 2.8 months in the azacitidine trial, suggesting that the decitabine patients had more aggressive disease ([@b61]; [@b28]). In addition, response criteria in the azacitidine trial were less rigorous, requiring a CR or PR for at least 4 weeks and not requiring disappearance of dysplastic changes ([@b61]), compared with the decitabine study in which response was determined using IWG criteria ([@b28]).

Future considerations
=====================

Clinical studies are now under way to evaluate combination therapy with decitabine and other agents. Farthest along in development is the combination of decitabine and histone deacetylase (HDAC) inhibitors such as valproic acid. Results from a recent phase 1/2 study of decitabine and valproic acid suggest that this combination has significant activity in patients with AML and MDS and is associated with changes in histone acetylation and DNA hypomethylation ([@b20]). Other agents that are being studied in combination with decitabine include amsacrine, idarubicin, daunorubicin, topotecan, cisplatin, carboplatin, and imatinib ([@b47]; [@b19]).

Decitabine therapy, alone and in combination with other agents, has shown encouraging results in other studies involving AML patients ([@b50]; [@b39]; [@b46]; [@b45]; [@b35]). Preliminary results from a recent phase 2 study in AML patients not eligible for induction chemotherapy suggest that decitabine is an active first-line treatment ([@b35]). Decitabine was administered at a dose of 135 mg/m^2^ IV over 72 hours repeated every 6 weeks for up to four courses, with all-transretinoic acid (ATRA) administered at a dose of 45 mg/m^2^ per day for 28 days during the second course in decitabine-sensitive patients. In the 29 fully evaluable patients, a CR was observed in four patients (14%) and a PR was observed in five patients (17%). Toxicities with decitabine were similar to those described for MDS, and no unexpected toxicities were observed with the combination of decitabine plus ATRA.

Although not within the scope of this review, decitabine is also being evaluated in chronic myelogenous leukemia (CML) ([@b55]; [@b31]; [@b25]) and in some solid tumors including renal, ovarian, colorectal, and cervical cancer ([@b64]; [@b1]; [@b60]; [@b11]; [@b38]; [@b63]; [@b58]; [@b47]; [@b56]; [@b62]; [@b21]).

Summary
=======

Results from phase 2 and phase 3 studies indicate that decitabine is effective in the treatment of MDS, resulting in durable clinical responses and delayed time to AML transformation or death.

Decitabine has been shown to be well tolerated, with a toxicity profile expected for this class of agents. Recent studies suggest that the efficacy of decitabine may be further optimized by allowing for multiple treatment cycles and by using lower-dose schedules such as a schedule of 20 mg/m^2^ IV over 1 hour daily for 5 days. Future directions for decitabine include its use in combination therapy with agents such as HDAC inhibitors and in AML.
